Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction.

Autor: Naeem F; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Leone TC; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Petucci C; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Shoffler C; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Kodihalli RC; Drug Safety R&D, Pfizer Inc, Groton, CT., Hidalgo T; Translational Clinical Sciences, Pfizer Inc, Groton, CT., Tow-Keogh C; Translational Clinical Sciences, Pfizer Inc, Groton, CT., Mancuso J; Early Clinical Development, Pfizer Inc, Cambridge MA., Tzameli I; Early Clinical Development, Pfizer Inc, Cambridge MA., Bennett D; Early Clinical Development, Pfizer Inc, Cambridge MA., Groarke JD; Internal Medicine Research Unit, Pfizer Inc, Cambridge MA., Flach RJR; Internal Medicine Research Unit, Pfizer Inc, Cambridge MA., Rader DJ; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Cardiovascular Institute, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Kelly DP; Cardiovascular Institute, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.